Saturday 17 October 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22,375.6%, EPS grew 48.2% and free cash flow fell 9.01%, each against the same quarter a year earlier.
36.05
1.40
−3.74%
Follow SEPN
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 3.68 | 3.41 |
P/S ratio |
58.37 | 210.70 | 26.85 |
Altman Z″-Score (non-manufacturers) |
4.01 | 14.99 | 3.75 |
P/FCF ratio |
0.00 | 0.00 | 10.10 |
Beneish M-Score |
— | 2.67 | 32.85 |
P/Operating CF |
(3.11) | (10.81) | (82.33) |
P/B ratio |
0.00 | 0.54 | 3.23 |
Price to Tangible BV |
0.00 | 0.54 | 3.23 |
EV/Sales |
(87.31) | (115.74) | 18.34 |
EV/EBITDA |
1.17 | 1.57 | 0.00 |
EV/Operating CF |
1.41 | 1.84 | 7.65 |
EV/FCF |
2.21 | 2.65 | 6.90 |
Quick Ratio |
16.09 | 27.32 | 4.62 |
Current Ratio |
16.30 | 27.77 | 4.73 |
Net Debt/EBITDA |
(30.27) | 4.42 | 5.86 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.09 |
Operating CF/Net income |
(68.29) | 0.94 | (2.25) |
Capex/Depreciation |
26.09 | 14.65 | 7.47 |
| 0.00% | (37.62%) | (12.19%) | |
| 0.00% | (24.45%) | (9.29%) | |
ROIC |
0.00% | (73.08%) | 0.00% |
Return on Tangible Assets |
0.51% | (20.57%) | (14.88%) |
Average Days of Receivables |
55,054.57 | 58.06 | 82.26 |
Research and Development Expense of Revenue |
23,827.15% | 6,077.86% | 212.37% |
Selling, General and Administrative Expense of Revenue |
6,438.41% | 1,540.56% | 63.47% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,072.85% | 293.21% | 18.45% |
Graham Net Nets |
(2.45) | 1.41 | 0.16 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(127.24%) | (97.90%) | (3.98%) |
Free Cash Flow Yield |
(67.71%) | (20.73%) | 9.90% |
Revenue per Share |
0.08 | 0.11 | 1.04 |
Operating CF per Share |
(20.07) | (6.82) | 2.49 |
Capex per Share |
11.47 | 2.07 | 0.27 |
Free Cash Flow per Share |
(8.61) | (4.75) | 2.76 |
Cash per Share |
45.87 | 35.48 | 8.84 |
Shareholders Equity per Share |
(19.89) | 42.47 | 8.63 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(19.89) | 42.47 | 8.63 |
Free Cash Flow |
(16.60) | (46.95) | 122.17 |
Working Capital |
105.76 | 343.98 | 324.03 |
Capital Expenditures |
22.12 | 20.52 | 11.98 |
Net Current Asset Value |
(56.56) | 320.32 | 196.70 |
EV/EBIT |
1.15 | 1.54 | 0.00 |
Capex to Sales |
(146.50) | (19.09) | (0.26) |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.18 | 0.28 | 0.36 |
Cash ROIC |
(33.13%) | (6.09%) | 15.80% |
Accounts Receivable Turnover |
0.00 | 0.09 | 8.73 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
— | 11.47 | 5.26 |
Average Payables |
— | 2.92 | 6.74 |
Average Assets |
— | 293.71 | 526.37 |
Average Common Equity |
— | 190.84 | 400.99 |
Columns are period end dates